Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Forskere ... Innovation in Science", som finner sted i ... på nett, på  http://www.openinnovationinscience.at , og søknadsperioden ... De to største utfordringene innen helsevitenskapen ... nye forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, ...
(Date:7/2/2015)... July 2, 2015  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today announced a litigation ... Incorporated v. Verizon Services Corp. et al. , Case ... the Eastern District of Virginia , ... 2015 interpreting certain key claims in favor of the ...
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
Breaking Biology Technology:Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... marketers scrambling for content instead of search engine rankings. ... out its new search algorithm in late November it ... had enjoyed top ranking with free listings in their ... off. Their free ride was over. , ,Googles decision ...
... to spend $127 billion dollars on research and development in ... of spending this multi-billion dollar river of R & D ... looking for appropriate projects to fund. , ,Some of ... a retired U.S. Air Force officer who now is an ...
... CHICAGO Watching the Midwest technology job market these days is an ... giving hope that things are truly turning around. , ,At the ... More and more often, when we tell them about jobs we've spotted, ... List or ChicWIT or Monster.com ) you wrote ...
Cached Biology Technology:Garbage In, Garbage Out: The Dirt on Googles New Algorithm 2Billions with a B for R&D 2Billions with a B for R&D 3Pity the Midwest Technology Sales Guy 2Pity the Midwest Technology Sales Guy 3Pity the Midwest Technology Sales Guy 4Pity the Midwest Technology Sales Guy 5
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... and take part in the region,s most important osteoporosis ... delegates in Kuala Lumpur and enjoy a high quality ... advances to help you in your clinical practice. ... Earn 17 European CME credits / 20 CPD ...
... 2012   Masimo (NASDAQ: MASI ) today ... 24th Annual Piper Jaffray Health Care Conference at the New York ... 2:00 p.m. Eastern Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... The Ebola, Marburg and Lassa viruses are commonly referred to ... have been around for centuries. In a perspective in ... researchers including a professor at The University of Texas Health ... appropriate to refer to these viruses as emerging diagnoses. ...
Cached Biology News:Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 2Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 3Scientists question the designation of some emerging diseases 2Scientists question the designation of some emerging diseases 3
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
Biology Products: